Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377015617> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4377015617 endingPage "S110" @default.
- W4377015617 startingPage "S109" @default.
- W4377015617 abstract "Multiple randomized controlled trials have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) decrease the composite endpoint of cardiovascular death or heart failure hospitalizations in heart failure patients. But it is uncertain whether SGLT2i impact the risk of sudden cardiac death in these patients with heart failure. We conducted a meta-analysis of SGLT2i randomized controlled trials to determine the impact of SGLT2i therapy on arrhythmic outcomes in patients with heart failure receiving optimal medical therapy. A comprehensive search was performed to identify relevant data published prior to August 28, 2022. Randomized controlled trials were included if: 1) all patients had clinical heart failure 2) SGLT2i and placebo were compared 3) all patients received conventional medical therapy and 4) there were the reported outcomes of interest (SCD, ventricular arrhythmias, atrial arrhythmias). SCD was reported in seven of the eleven trials meeting selection criteria. Taken together, 10,796 patients received SGLT2i and 10,796 received placebo. SGLT2i therapy was associated with a significant reduction in the risk of SCD (RR 0.68; 95% CI 0.48–0.95; p = 0.03) with minimal heterogeneity between studies (I2 = 0%). Without the benefit of dedicated rhythm monitoring, there were no significant differences in the incidence of sustained ventricular arrhythmias not associated with SCD (RR 1.03; 95% CI, 0.83–1.29; p = 0.77; I2 = 0%) or atrial arrhythmias (RR 0.91; 95% CI, 0.77–1.09; p = 0.31; I2 = 29%) between patients receiving an SGLT2i vs placebo. SGLT2i therapy is associated with a reduced risk of SCD in patients with heart failure receiving contemporary medical therapy." @default.
- W4377015617 created "2023-05-19" @default.
- W4377015617 creator A5004072348 @default.
- W4377015617 creator A5009565927 @default.
- W4377015617 creator A5013824407 @default.
- W4377015617 creator A5016173778 @default.
- W4377015617 creator A5025746169 @default.
- W4377015617 creator A5031317961 @default.
- W4377015617 creator A5042772889 @default.
- W4377015617 creator A5045400007 @default.
- W4377015617 creator A5059900315 @default.
- W4377015617 creator A5063097243 @default.
- W4377015617 creator A5091734035 @default.
- W4377015617 date "2023-05-01" @default.
- W4377015617 modified "2023-09-27" @default.
- W4377015617 title "MP-453091-3 SGLT2 INHIBITORS REDUCE RISK OF SUDDEN CARDIAC DEATH IN PATIENTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS" @default.
- W4377015617 doi "https://doi.org/10.1016/j.hrthm.2023.03.425" @default.
- W4377015617 hasPublicationYear "2023" @default.
- W4377015617 type Work @default.
- W4377015617 citedByCount "0" @default.
- W4377015617 crossrefType "journal-article" @default.
- W4377015617 hasAuthorship W4377015617A5004072348 @default.
- W4377015617 hasAuthorship W4377015617A5009565927 @default.
- W4377015617 hasAuthorship W4377015617A5013824407 @default.
- W4377015617 hasAuthorship W4377015617A5016173778 @default.
- W4377015617 hasAuthorship W4377015617A5025746169 @default.
- W4377015617 hasAuthorship W4377015617A5031317961 @default.
- W4377015617 hasAuthorship W4377015617A5042772889 @default.
- W4377015617 hasAuthorship W4377015617A5045400007 @default.
- W4377015617 hasAuthorship W4377015617A5059900315 @default.
- W4377015617 hasAuthorship W4377015617A5063097243 @default.
- W4377015617 hasAuthorship W4377015617A5091734035 @default.
- W4377015617 hasBestOaLocation W43770156171 @default.
- W4377015617 hasConcept C126322002 @default.
- W4377015617 hasConcept C142724271 @default.
- W4377015617 hasConcept C164705383 @default.
- W4377015617 hasConcept C168563851 @default.
- W4377015617 hasConcept C203092338 @default.
- W4377015617 hasConcept C204787440 @default.
- W4377015617 hasConcept C27081682 @default.
- W4377015617 hasConcept C2775935837 @default.
- W4377015617 hasConcept C2778198053 @default.
- W4377015617 hasConcept C44249647 @default.
- W4377015617 hasConcept C71924100 @default.
- W4377015617 hasConcept C82789193 @default.
- W4377015617 hasConcept C95190672 @default.
- W4377015617 hasConceptScore W4377015617C126322002 @default.
- W4377015617 hasConceptScore W4377015617C142724271 @default.
- W4377015617 hasConceptScore W4377015617C164705383 @default.
- W4377015617 hasConceptScore W4377015617C168563851 @default.
- W4377015617 hasConceptScore W4377015617C203092338 @default.
- W4377015617 hasConceptScore W4377015617C204787440 @default.
- W4377015617 hasConceptScore W4377015617C27081682 @default.
- W4377015617 hasConceptScore W4377015617C2775935837 @default.
- W4377015617 hasConceptScore W4377015617C2778198053 @default.
- W4377015617 hasConceptScore W4377015617C44249647 @default.
- W4377015617 hasConceptScore W4377015617C71924100 @default.
- W4377015617 hasConceptScore W4377015617C82789193 @default.
- W4377015617 hasConceptScore W4377015617C95190672 @default.
- W4377015617 hasIssue "5" @default.
- W4377015617 hasLocation W43770156171 @default.
- W4377015617 hasOpenAccess W4377015617 @default.
- W4377015617 hasPrimaryLocation W43770156171 @default.
- W4377015617 hasRelatedWork W1885119863 @default.
- W4377015617 hasRelatedWork W2073750123 @default.
- W4377015617 hasRelatedWork W2114346778 @default.
- W4377015617 hasRelatedWork W2230641066 @default.
- W4377015617 hasRelatedWork W2335438131 @default.
- W4377015617 hasRelatedWork W2531052508 @default.
- W4377015617 hasRelatedWork W2592774827 @default.
- W4377015617 hasRelatedWork W2626084264 @default.
- W4377015617 hasRelatedWork W2903890959 @default.
- W4377015617 hasRelatedWork W4212933565 @default.
- W4377015617 hasVolume "20" @default.
- W4377015617 isParatext "false" @default.
- W4377015617 isRetracted "false" @default.
- W4377015617 workType "article" @default.